Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-547 in super-refractory status epilepticus
NCT02477618Phase 3Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Jun 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of brexanolone in status epilepticus (SE), sponsored by Supernus Pharmaceuticals, Inc.. Started Jun 2015; status: completed.
02
Drugs
brexanolone
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT02477618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477618.